title: Radiotherapy without steroids in selected metastatic spinal cord compression patients. A phase II trial.
abstract: A phase II trial was planned to investigate the feasibility of radiotherapy (RT) without steroids in 20 consecutive patients with metastatic spinal cord compression (MSCC), no neurologic deficits, or only radiculopathy, and no massive invasion of the spine at magnetic resonance imaging (MRI) or computed tomography (CT). Aiming at an early diagnosis, MRI or CT was prescribed for all cancer patients with back pain and osteolysis, even when there were no signs of neurologic spinal compression. All patients were given 30 Gy in 10 fractions over 2 weeks with no steroids. Back pain and motor capacity were the parameters adopted to verify response to RT. Sixteen of 20 patients (80%) were able to walk without support, and 14 (70%) had no radiculopathy. Seventeen of 20 cases (85%) achieved relief from back pain. Regarding motor function, all patients (100%) responded to RT because the 16 patients able to walk without support at diagnosis did not deteriorate and the other 4, who needed support, became ambulatory without motor impairment. Median survival time was 14 months. Eight of 20 (40%) treated patients are still alive (14 to 36 months after end of RT), fully ambulatory, and free from relapse in the treated spine. Acute side effects were documented in only 2 patients (10%) and were managed without steroids. The results of this study suggest that RT without steroids is a feasible regimen for MSCC patients with good motor function. Elimination of steroids from the standard treatment for MSCC avoids cortisone side effects above all in those patients with diabetes, hypertension, peptic ulcer, and other steroid-sensitive medical problems.
authors.affiliation: Department of Radiation Oncology, Policlinico Monteluce, Perugia, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Maranzano
authors.forename: P
authors.initials: P
authors.lastname: Latini
authors.forename: S
authors.initials: S
authors.lastname: Beneventi
authors.forename: E
authors.initials: E
authors.lastname: Perruci
authors.forename: B M
authors.initials: BM
authors.lastname: Panizza
authors.forename: C
authors.initials: C
authors.lastname: Aristei
authors.forename: M
authors.initials: M
authors.lastname: Lupattelli
authors.forename: M
authors.initials: M
authors.lastname: Tonato
mesh_terms: D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D001416:Back Pain / Q000209:etiology / Q000532:radiotherapy; D003348:Cortisone / Q000009:adverse effects; D003920:Diabetes Mellitus / Q000503:physiopathology; D018572:Disease-Free Survival; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D006973:Hypertension / Q000503:physiopathology; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010014:Osteolysis / Q000209:etiology / Q000532:radiotherapy; D010437:Peptic Ulcer / Q000503:physiopathology; D010523:Peripheral Nervous System Diseases / Q000209:etiology / Q000532:radiotherapy; D013117:Spinal Cord Compression / Q000175:diagnosis / Q000209:etiology* / Q000532:radiotherapy*; D013122:Spinal Diseases / Q000209:etiology / Q000532:radiotherapy; D013125:Spinal Neoplasms / Q000532:radiotherapy / Q000556:secondary*; D013126:Spinal Nerve Roots / Q000473:pathology; D015996:Survival Rate; D014057:Tomography, X-Ray Computed; D016138:Walking
chemical_list: D000893:Anti-Inflammatory Agents; D003348:Cortisone